<DOC>
	<DOCNO>NCT01362231</DOCNO>
	<brief_summary>The study consist 2 part : Part A randomized , multiple-dose , double-blind , placebo-controlled sequential dose escalation study evaluate GS-6624 subject Idiopathic Pulmonary Fibrosis ( IPF ) complete October 2011 . Part B randomize , two-dose , open-label dose expansion study evaluate GS-6624 subject IPF currently enrol .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy GS-6624 ( Formerly AB0024 ) Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>The primary objective study characterize safety , tolerability , PK GS-6624 multiple IV administration patient IPF . The secondary objective evaluate formation anti-GS-6624 antibody measure effect GS-6624 FVC , DLCO , SGRQ score . A total 48 patient enrol . In double-blind phase ( Part A ) , total 18 patient enrol 3 dose level . Part A complete October 2011 . In Part B , 30 patient enrol 2 dose level . Part B open-label currently enrol .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>1 . Acceptable result pulmonary function test 2 . At rest oxygen saturation â‰¥90 % room air 3 . Adequate organ function 1 . High resolution computer tomography pattern show emphysema great fibrosis 2 . Acceptable result whole body plethysmography 3 . History clinically significant hepatic renal disease 4 . Poorly control severe diabetes mellitus 5 . Use systemic immunosuppressant within 28 day GS6624 infusion</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Fibrosis</keyword>
	<keyword>Pulmonary Fibrosis</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Interstitial</keyword>
</DOC>